A bacteriophage, VP882, has been identified to use bacterial quorum-sensing as a method to control the lysis-lysogeny decision. This is the first time a virus has been shown to detect a bacterial molecule.
Take a look behind the scenes of a recent Future Microbiology paper as we ask the authors about the challenges in treating respiratory tract infections and how nanomedicines could help.
New research has suggested that the spread of prions to the brain does not occur via the blood–brain barrier, implicating other mechanisms.
Positive results for zoliflodacin, EMA approval for fexinidazole and Merck cuts rotavirus commitment – take a look a the month’s industry headlines.
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
A Phase II, muti-center, randomized, open-label trial has reported that a novel oral antibiotic, zoliflodacin, is effective in the treatment of uncomplicated urogenital gonorrhea.
In this article, the authors discuss their research using non-ribosome targeting tobramycin-based adjuvants to overcome the intrinsic resistance observed in bacteria, Pseudomonas aeruginosa.
In recent years, researchers have discovered the potential of CRISPR as an antimicrobial. In this blog post we explain the recent advances made in this field and the different approaches by which CRISPR can be used as a new weapon in the battle against antimicrobial resistance.
A Phase II trial has demonstrated that a new investigational antibiotic, cefiderocol, is as effective as the current standard-of-care for treating complicated UTIs caused by multi-drug resistant bacteria.
Roche has announced the FDA approval of Xofluza™, the first and only single-dose oral medicine approved to treat flu.
